Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SGMO – Sangamo Therapeutics, Inc.

Float Short %

5.29

Margin Of Safety %

Put/Call OI Ratio

0.39

EPS Next Q Diff

0.07

EPS Last/This Y

0.08

EPS This/Next Y

0.18

Price

0.44

Target Price

3.25

Analyst Recom

2.2

Performance Q

-14.43

Relative Volume

0.76

Beta

1.29

Ticker: SGMO



19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17SGMO0.4110.280.28116871
2025-11-18SGMO0.42010.280.00116992
2025-11-19SGMO0.39340.270.36118845
2025-11-20SGMO0.3850.280.10118999
2025-11-21SGMO0.430.270.21119518
2025-11-24SGMO0.41730.350.1293553
2025-11-25SGMO0.42420.340.0395808
2025-11-26SGMO0.46030.340.3396695
2025-12-01SGMO0.42590.330.1797849
2025-12-02SGMO0.4410.330.5598114
2025-12-03SGMO0.49930.340.2598987
2025-12-04SGMO0.530.340.0498835
2025-12-05SGMO0.49490.340.0399779
2025-12-08SGMO0.50180.340.3699408
2025-12-09SGMO0.49970.3415.8599821
2025-12-10SGMO0.48290.361.44101502
2025-12-11SGMO0.45990.3610.50101593
2025-12-12SGMO0.450.390.23103660
2025-12-15SGMO0.440.394.68103807
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1



19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17SGMO0.4231.8- -0.41
2025-11-18SGMO0.4231.8- -0.41
2025-11-19SGMO0.3931.8- -0.41
2025-11-20SGMO0.3931.8- -0.41
2025-11-21SGMO0.4331.8- -0.41
2025-11-24SGMO0.4231.8- -0.41
2025-11-25SGMO0.4231.8- -0.41
2025-11-26SGMO0.4631.8- -0.41
2025-12-01SGMO0.4331.8- -0.41
2025-12-02SGMO0.4431.8- -0.41
2025-12-03SGMO0.5031.8- -0.41
2025-12-04SGMO0.5331.8- -0.41
2025-12-05SGMO0.5031.8- -0.41
2025-12-08SGMO0.5031.8- -0.41
2025-12-09SGMO0.5031.8- -0.41
2025-12-10SGMO0.4931.8- -0.41
2025-12-11SGMO0.4631.8- -0.41
2025-12-12SGMO0.4531.8- -0.41
2025-12-15SGMO0.4431.8- -0.41
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17SGMO0.002.414.32
2025-11-18SGMO0.002.414.32
2025-11-19SGMO0.002.414.32
2025-11-20SGMO0.002.414.32
2025-11-21SGMO0.002.414.32
2025-11-24SGMO0.003.734.32
2025-11-25SGMO0.003.734.32
2025-11-26SGMO0.003.733.56
2025-12-01SGMO0.00-3.263.56
2025-12-02SGMO0.00-3.263.56
2025-12-03SGMO0.00-3.263.56
2025-12-04SGMO0.00-3.263.56
2025-12-05SGMO0.00-3.263.56
2025-12-08SGMO0.00-3.253.56
2025-12-09SGMO0.00-3.253.56
2025-12-10SGMO0.00-3.255.31
2025-12-11SGMO0.00-3.255.31
2025-12-12SGMO0.00-3.255.31
2025-12-15SGMO0.00-3.255.29
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="SGMO" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

-0.11

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

-0.04

Insider Transactions

Institutional Transactions

-3.25

Beta

1.29

Average Sales Estimate Current Quarter

40

Average Sales Estimate Next Quarter

20

Fair Value

Quality Score

3

Growth Score

24

Sentiment Score

15

Actual DrawDown %

97.7

Max Drawdown 5-Year %

-98.4

Target Price

3.25

P/E

Forward P/E

PEG

P/S

4.5

P/B

22.69

P/Free Cash Flow

EPS

-0.44

Average EPS Est. Cur. Y​

-0.41

EPS Next Y. (Est.)

-0.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-331.28

Relative Volume

0.76

Return on Equity vs Sector %

-1771.5

Return on Equity vs Industry %

-1756.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”SGMO” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SGMO” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SGMO” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SGMO” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SGMO” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SGMO” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”SGMO” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Sangamo Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 183
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
stock quote shares SGMO – Sangamo Therapeutics, Inc. Stock Price stock today
news today SGMO – Sangamo Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SGMO – Sangamo Therapeutics, Inc. yahoo finance google finance
stock history SGMO – Sangamo Therapeutics, Inc. invest stock market
stock prices SGMO premarket after hours
ticker SGMO fair value insiders trading